Encompass Health Co. (NYSE:EHC) CAO Andrew L. Price Sells 5,042 Shares of Stock

Encompass Health Co. (NYSE:EHC) CAO Andrew L. Price sold 5,042 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the transaction, the chief accounting officer now directly owns 69,164 shares in the company, valued at approximately $6,798,129.56. This represents a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Encompass Health Price Performance

Encompass Health stock opened at $100.10 on Friday. The stock has a market cap of $10.08 billion, a price-to-earnings ratio of 22.44, a price-to-earnings-growth ratio of 1.18 and a beta of 0.90. The firm has a 50-day moving average of $96.00 and a two-hundred day moving average of $95.46. Encompass Health Co. has a 1 year low of $72.57 and a 1 year high of $104.55. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a return on equity of 18.06% and a net margin of 8.48%. On average, research analysts forecast that Encompass Health Co. will post 4.76 earnings per share for the current year.

Hedge Funds Weigh In On Encompass Health

A number of hedge funds and other institutional investors have recently made changes to their positions in EHC. Cetera Investment Advisers lifted its stake in Encompass Health by 5.7% in the second quarter. Cetera Investment Advisers now owns 12,353 shares of the company’s stock worth $1,060,000 after acquiring an additional 664 shares during the period. CWM LLC grew its position in shares of Encompass Health by 27.8% in the 3rd quarter. CWM LLC now owns 8,164 shares of the company’s stock worth $789,000 after buying an additional 1,776 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Encompass Health by 387.7% during the 3rd quarter. UMB Bank n.a. now owns 317 shares of the company’s stock valued at $31,000 after purchasing an additional 252 shares during the last quarter. Creative Planning raised its stake in Encompass Health by 4.1% in the third quarter. Creative Planning now owns 19,086 shares of the company’s stock valued at $1,844,000 after buying an additional 743 shares during the last quarter. Finally, V Square Quantitative Management LLC raised its position in shares of Encompass Health by 53.0% in the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock valued at $39,000 after purchasing an additional 140 shares during the last quarter. Institutional investors own 97.25% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Truist Financial reaffirmed a “buy” rating and set a $116.00 price objective (up from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. Barclays lifted their price target on shares of Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a report on Friday, February 7th. KeyCorp increased their price objective on shares of Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a research note on Monday. StockNews.com downgraded shares of Encompass Health from a “buy” rating to a “hold” rating in a report on Friday, February 7th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $110.00 target price on shares of Encompass Health in a research report on Tuesday. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $107.67.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.